Clinical and treatment characteristics of targeted therapy courses
| Vemurafenib (n=19) | Cobimetinib (n=9) | |
| Age at last follow-up visit, years | 59.3±12.8 | 56.2±12.4 |
| Male sex (%) | 17 (90) | 6 (66) |
| BRAF V600E mutation (%) | 19 (100) | 3 (33) |
| Clinical manifestations (%) | ||
| Cardiovascular | 13 (68) | 56 (67) |
| Pleuropulmonary | 13 (68) | 6 (67) |
| Neurological and/or orbital | 18 (95) | 9 (100) |
| Retroperitoneal | 16 (84) | 6 (67) |
| Skeletal | 19 (100) | 9 (100) |
| Previous therapies (%) | 16 (84) | 8 (89) |
| Targeted therapy | 1 (5) | 2 (22) |
| Interferon-α-2a | 12 (63) | 3 (33) |
| Glucocorticoid | 8 (42) | 1 (11) |
| Methotrexate | 3 (16) | 1 (11) |
| Tocilizumab | 1 (5) | 0 (0) |
| Anakinra | 0 (0) | 3 (33) |
| Infliximab | 1 (5) | 0 (0) |
| Imatinib | 1 (5) | 0 (0) |
| Tofacitinib | 0 (0) | 1 (11) |
| Concomitant therapies (%) | 8 (42) | 5 (56) |
| Glucocorticoids | 8 (42) | 1 (11) |
| Anakinra | 2 (11) | 5 (56) |
| Adverse reactions (%) | 11 (58) | 4 (44) |
| Renal | 6 (32) | 1 (11) |
| Cutaneous | 5 (26) | 3 (33) |
| Systemic inflammation | 2 (11) | 1 (11) |
| Cardiovascular | 3 (16) | 1 (11) |
| Haematological | 0 (0) | 1 (11) |
| Mucosal/gastrointestinal | 0 (0) | 4 (44) |
| Hepatic | 1 (5) | 0 (0) |
| Treatment discontinued (%) | 5 (26) | 3 (33) |